{"podcast":{"title":"Hims House","slug":"hims-house-7026583","podcast_index_feed_id":7026583,"rss_url":"https://anchor.fm/s/10e9c0874/podcast/rss","website_url":"https://himshouse.substack.com/podcast","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/45300741/1466fea8bed61dc7.jpg","author":"Jonathan Stern","episode_count":73,"summary":"Hims House is the ultimate podcast for Hims & Hers investors. Hosted by Jonathan Stern and Patrick Lester, Hims House breaks down all the key questions shaping $HIMS — from telehealth and pharma to GLP-1s, compounding, and the future of healthcare. New episodes every week. himshouse.substack.com","last_synced_at":"2026-07-08T00:20:15.279819+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583"},"episode":{"title":"🚨 Hims launches GLP-1 pill, Novo Nordisk threatens to sue!!! (emergency pod with Cremieux)","slug":"hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux","published_at":"2026-02-05T23:25:05+00:00","page_url":"https://stenobird.com/podcast/hims-house-7026583/hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux","show_page_url":"https://stenobird.com/podcast/hims-house-7026583","url":"https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Hims-launches-GLP-1-pill--Novo-Nordisk-threatens-to-sue----emergency-pod-with-Cremieux-e3emv1p","audio_url":"https://anchor.fm/s/10e9c0874/podcast/play/115096057/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-5%2F417557760-44100-2-bca9c07fb9c94.mp3","summary":"EMERGENCY EPISODE!!! Hims has launched a compounded oral semaglutide (GLP-1) pill, immediately triggering legal threats from Novo Nordisk. Jonathan Stern is joined by Cremieux, a bioinformatician and leading GLP-1 researcher, to break down what Hims actually released and why the drug-delivery mechanism matters. The conversation examines liposomal delivery vs. Novo’s proprietary SNAC technology, whether Hims’ product will work at all, and whether Novo will sue / how things might shake out if they do. The episode closes with a look at unit economics, next-gen GLP-1s, and what this gambit means for Hims, Novo, and the broader obesity drug market. 00:00 Sponsor: Mochi Health 02:24 Initial reaction to the news 03:56 Science deep dive: liposomal delivery vs. SNAC 06:02 Legal implications and possible lawsuit 18:38 Future of the GLP-1 market (retatrutide, Viking, orforglipron) 25:03 Final risk assessment and conclusions Not financial, legal, or medical advice","meta_description":"EMERGENCY EPISODE!!! Hims has launched a compounded oral semaglutide (GLP-1) pill, immediately triggering legal threats from Novo Nordisk. Jonathan Stern…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1706,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hims-house-7026583/hims-launches-glp-1-pill-novo-nordisk-threatens-to-sue-emergency-pod-with-cremieux.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}